
AlloVir ALVR
AlloVir EV - Enterprise Value | ALVR
Annual EV - Enterprise Value AlloVir
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -55.1 M | 68.2 M | -41.6 M | 422 M | 672 M | 1.25 B | 191 M | 55.9 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.25 B | -55.1 M | 321 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Kadmon Holdings, Inc.
KDMN
|
27.5 B | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
-22.9 M | - | - | $ 256 M | ||
|
argenx SE
ARGX
|
40.2 B | $ 926.42 | -1.66 % | $ 56.8 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-61.5 M | $ 2.33 | -7.25 % | $ 19.8 M | ||
|
Zai Lab Limited
ZLAB
|
21.4 B | $ 21.01 | -4.16 % | $ 23 B | ||
|
Neos Therapeutics, Inc.
NEOS
|
-14.1 M | - | -2.54 % | $ 57.2 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
229 M | $ 1.37 | 0.74 % | $ 98.5 M | ||
|
Zoetis
ZTS
|
65.9 B | $ 78.81 | -2.47 % | $ 34.9 B | ||
|
Odonate Therapeutics, Inc.
ODT
|
5.24 B | - | -3.18 % | $ 58.5 M | ||
|
Orphazyme A/S
ORPH
|
284 M | - | -2.25 % | $ 31.3 M | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
6.61 B | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
29.5 K | - | - | $ 1.77 B | ||
|
Xenetic Biosciences
XBIO
|
-2.54 M | $ 1.47 | -4.55 % | $ 2.5 M | ||
|
Translate Bio, Inc.
TBIO
|
1.43 B | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
83.6 M | - | - | $ 1.94 B | ||
|
Urovant Sciences Ltd.
UROV
|
37.4 B | - | - | $ 532 M | ||
|
Acceleron Pharma Inc.
XLRN
|
-182 M | - | - | $ 10.9 B | ||
|
Zogenix, Inc.
ZGNX
|
18.2 B | - | -4.97 % | $ 664 M | ||
|
Yunhong International
ZGYH
|
18.2 B | - | 0.10 % | $ 92.2 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
96.3 B | - | -7.58 % | $ 264 M | ||
|
Taysha Gene Therapies
TSHA
|
1.23 B | $ 3.71 | -1.72 % | $ 1.19 B | ||
|
Vericel Corporation
VCEL
|
1.92 B | $ 57.41 | -1.46 % | $ 2.89 B | ||
|
Vir Biotechnology
VIR
|
1.02 B | $ 8.37 | -5.64 % | $ 1.16 B | ||
|
Veracyte
VCYT
|
2.78 B | $ 25.08 | 0.16 % | $ 1.97 B | ||
|
Viking Therapeutics
VKTX
|
3.09 B | $ 24.72 | -4.35 % | $ 2.79 B | ||
|
Vanda Pharmaceuticals
VNDA
|
435 M | $ 3.44 | -6.27 % | $ 203 M | ||
|
VistaGen Therapeutics
VTGN
|
3.96 M | $ 0.16 | -12.33 % | $ 6.09 M | ||
|
Voyager Therapeutics
VYGR
|
232 M | $ 1.52 | -5.9 % | $ 89.2 M | ||
|
Verrica Pharmaceuticals
VRCA
|
58.9 M | $ 2.74 | -5.03 % | $ 29.2 M | ||
|
Wave Life Sciences Ltd.
WVE
|
2.11 B | $ 2.56 | -6.07 % | $ 432 M | ||
|
XBiotech
XBIT
|
-45.4 M | $ 1.75 | 4.17 % | $ 53.4 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
860 M | $ 1.37 | -7.43 % | $ 922 M | ||
|
Adial Pharmaceuticals
ADIL
|
-3.17 M | $ 3.15 | -35.42 % | $ 2.11 M | ||
|
ADMA Biologics
ADMA
|
3.84 B | $ 13.18 | -1.2 % | $ 3.14 B | ||
|
Exicure
XCUR
|
35.4 M | $ 0.96 | -7.24 % | $ 6.05 M | ||
|
Xencor
XNCR
|
1.08 B | $ 33.48 | -1.56 % | $ 2.49 B | ||
|
Cortexyme
CRTX
|
123 M | - | -1.05 % | $ 67.1 M | ||
|
Burford Capital Limited
BUR
|
5.73 B | $ 3.24 | -5.55 % | $ 710 M | ||
|
Daré Bioscience
DARE
|
21.8 M | $ 0.41 | -9.93 % | $ 4.58 M | ||
|
Fate Therapeutics
FATE
|
140 M | $ 0.92 | -9.07 % | $ 109 M | ||
|
Greenwich LifeSciences
GLSI
|
386 M | $ 19.09 | -3.54 % | $ 258 M | ||
|
Halozyme Therapeutics
HALO
|
12 B | $ 91.28 | -1.89 % | $ 10.9 B | ||
|
Hutchison China MediTech Limited
HCM
|
12.4 B | $ 13.18 | -2.04 % | $ 11.3 B | ||
|
Aptorum Group Limited
APM
|
8.14 M | - | - | $ 5.72 M | ||
|
iBio
IBIO
|
98.5 M | $ 0.83 | 3.01 % | $ 86.4 M | ||
|
Kodiak Sciences
KOD
|
2.01 B | $ 97.05 | -0.87 % | $ 5.16 B | ||
|
Karyopharm Therapeutics
KPTI
|
341 M | $ 0.02 | -56.5 % | $ 219 | ||
|
FSD Pharma
HUGE
|
4.15 M | - | 5743.5 % | $ 69.7 M | ||
|
BioAtla
BCAB
|
50.1 M | $ 1.74 | 0.64 % | $ 102 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
2.48 B | - | - | $ 3.85 B |